Core Viewpoint - The collaboration between Shanghai and Taizhou is expected to create new opportunities in the biopharmaceutical industry, enhancing innovation and development in the China Medical City [2] Group 1: Development and Innovation - Taizhou has a unique advantage in the biopharmaceutical sector, being home to the first national high-tech zone for pharmaceuticals and receiving significant policy support from Jiangsu provincial government [2] - The city has established various innovative platforms, including the International Genetic Engineering and Biotechnology Center and the Fudan University Health Science Research Institute, to foster a comprehensive innovation matrix for the biopharmaceutical industry [3] Group 2: Talent Acquisition and Industry Growth - Taizhou focuses on attracting high-level talent and entrepreneurs, having introduced 10 academicians, 75 national high-end experts, and 1,746 high-level talents under various talent programs, ensuring a strong talent foundation for industry development [4] - The city has attracted over 1,300 biopharmaceutical companies, including major players like AstraZeneca and Nestlé, with the health industry expected to exceed 400 billion yuan by 2025 [4] Group 3: Service and Future Prospects - Taizhou is committed to providing specialized, full-chain services to businesses, having established the first comprehensive drug supervision service center in China, which includes four service centers for new drug applications and regulatory reviews [5] - The city aims to leverage the integration of the Yangtze River Delta region to explore future growth areas such as synthetic biology, cell and gene therapy, AI pharmaceuticals, and high-end medical devices, positioning itself as a vibrant hub for biopharmaceutical innovation [5]

出品｜虎嗅科技组 作者｜陈伊凡、孙晓晨 编辑｜苗正卿 头图｜AI生成 "AI 原生 100" 是虎嗅科技组推出针对 AI 原生创新栏目，这是本系列的第「 10 」篇文章。 人类从未停止过与癌症、阿尔兹海默症、艾滋病等疾病等抗争。 但苦于新药研发的速度，这场疾病抗争史迟迟未能出线质的改变。而以生成式AI为基础的大模型的 出现，正在从根本上改变这一进程。 第一缕夕阳透过会议室玻璃窗，与C12的创始人兼CEO陈志刚的对话已经进行了两个半小时。生研 湾，我们这次谈话发生的地方，是大量新药的创新源头。陈志刚正在做的，是一个针对实验室场景的 通用机器人——这个机器人将会先被用在新药研发，之后泛化到新材料和化工等场景。 他厚厚的镜片反射出一道光——那是比窗外阳光更锐的东西，此时，全球药物研发行业创新浪潮正汹 涌来袭，AI已成为这场创新风暴的核心驱动力，这场能力，比10年前更大、更足。 2022年，陈志刚的公司C12成立，尝试将垂直领域的AI Agent与具身智能结合，突破湿实验（虎嗅 注：湿实验通常涉及生物样本、化学物质或其他液体材料的操作和处理。这类实验往往需要特定的实 验室条件,如无菌环境、温度控制等）的效率瓶颈。 一 ...

Core Viewpoint - The emergence of generative AI models is fundamentally transforming the drug development process, significantly accelerating the timeline for combating diseases like cancer and Alzheimer's [5][7]. Group 1: AI's Impact on Drug Development - Generative AI is expected to shorten the drug development cycle by 30%-50%, enhancing efficiency in various stages such as compound screening and clinical trial design [7]. - In the past month, nearly $10 billion in capital has flowed into the AI pharmaceutical sector, with major pharmaceutical companies forming over 20 significant partnerships with AI firms [5][6]. - A report by Evaluate Pharma predicts that the global prescription drug market will reach $1.756 trillion by 2030, with AI in drug development becoming a core growth engine [6]. Group 2: Company Insights - C12, founded by Chen Zhigang in 2022, focuses on developing a general-purpose robot for laboratory settings, initially targeting drug development and later expanding to new materials and chemicals [3][4]. - The company aims to address the efficiency bottlenecks in laboratory workflows, particularly in the purification stage, which is critical for clients [4][12]. - Chen Zhigang emphasizes that the company's decisions are driven by customer feedback, leading to a focus on automating labor-intensive tasks in the lab [4][11]. Group 3: Market Dynamics and Competition - C12 differentiates itself from competitors like JingTai and Insilico Medicine by focusing on the wet lab verification stage after AI has designed potential drug molecules [16][17]. - The traditional drug development process is lengthy and risky, with a success rate of less than 10%, but AI technologies are injecting new possibilities into this process [7][8]. - The company is exploring applications beyond pharmaceuticals, including new materials and chemical processes, indicating a broader market potential [38][50]. Group 4: Future Directions and Challenges - Chen Zhigang plans to refine the product and operations before seeking Series A funding, ensuring that clients perceive real value [11][69]. - The company is currently expanding its research team to meet increasing demand and is focused on understanding and addressing client needs [62][70]. - Future challenges include scaling operations and addressing new issues that arise as robots become more integrated into laboratory workflows [70][71].

Core Insights - The pharmaceutical industry is experiencing rapid advancements in drug discovery driven by artificial intelligence (AI), with AI-generated drugs moving into clinical stages this year [1][4] - Chinese innovative companies are leading globally in AI drug development, with McKinsey describing AI as a "once-in-a-century opportunity" for the pharmaceutical sector [1][5] Group 1: AI in Drug Discovery - AI is transforming drug design from "probabilistic collisions" to "atomic-level precision engineering," enabling faster and more accurate molecular design [4] - The success rate of AI-generated drug molecules in Phase I clinical trials has reached 80% to 90%, significantly higher than the historical average of 50% [4][5] - A notable study from Beijing Union Medical College and an AI pharmaceutical company demonstrated the ability to discover new targets and design new molecules using generative AI [5][9] Group 2: Investment and Financing - Nearly $10 billion has flowed into AI drug development globally in the first half of this year, indicating strong investor confidence in the sector [6][8] - The largest AI drug financing in China this year was approximately $123 million for the company Insilico Medicine, exceeding its target [6] - Major collaborations between multinational companies and Chinese firms are emerging, such as AstraZeneca's partnership with CSPC Pharmaceutical Group, valued at up to $5.3 billion [7][8] Group 3: Future Directions - The focus for companies is on advancing AI-discovered drugs from Phase I to Phase II and later clinical trials, addressing data bottlenecks in AI drug development [8] - Enhancing data sharing, standardization, and modeling algorithms is crucial for improving AI's capabilities in drug discovery [8][9] - Accurate data, including molecular information and biochemical interactions, is essential for AI to learn and propose useful drug candidates [9]

Core Viewpoint - The Hong Kong medical ETF (159366) has seen significant gains, driven by the booming market for innovative drugs and medical devices, with a notable increase of over 25% in the past month and a continuous rise for five consecutive days [1][4]. Group 1: ETF Performance - The Hong Kong medical ETF (159366) rose by 1.96% to 1.564, reflecting strong market interest [2]. - Over the past 5 days, the ETF has increased by 11.40%, and over the past 20 days, it has risen by 23.54% [2]. - The ETF is noted for having the highest concentration of CXO companies in the market, focusing on AI drug development, CXO, and medical devices [6]. Group 2: Company Developments - MicroPort Medical announced that Shanghai Shenda Capital has become a strategic shareholder, indicating the active role of merger funds in supporting local biopharmaceutical leaders [4]. - The strategic investment aims to enhance MicroPort Medical's position as a leader in high-end medical device innovation in China [4]. Group 3: Industry Insights - The National Healthcare Security Administration recently held a forum to discuss support for innovative drugs and medical devices, highlighting the significant policy, research, manufacturing, and market advantages of China's innovative drug and device sector [4]. - CXO leader WuXi AppTec reported a net profit of 8.56 billion yuan, a year-on-year increase of 101.9%, with a strong order backlog indicating robust growth potential [5]. - Market analysts suggest focusing on sectors with stable growth, particularly medical devices and pharmaceuticals, as the impact of centralized procurement is gradually diminishing [6].

Core Insights - The healthcare sector is a testing ground for new technologies, with generative AI significantly enhancing medical services and accelerating drug development [1][3] - The 2025 World Artificial Intelligence Conference in Shanghai showcased over 800 companies and 3000 cutting-edge exhibits, highlighting the rapid advancements in AI technology [1][2] Industry Trends - AI is transforming the entire healthcare process, including health management, diagnosis, imaging analysis, drug development, and surgical robotics, leading to improved efficiency and patient experience [3] - The AI healthcare market is projected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, indicating a positive future trend [3] Challenges in AI Healthcare - The industry faces significant challenges in moving from "technological feasibility" to "scalable application," including issues related to standardization, ecosystem fragmentation, and clinical translation [2][4] - Key barriers to commercialization include data privacy and compliance, clinical validation and payment models, operational capabilities, and interoperability within healthcare systems [4] Investment Landscape - Major tech companies like Tencent, Ant Group, and Huawei are increasingly focusing on the AI healthcare sector, indicating a shift from conceptualization to practical commercialization [3][4] - AI-native pharmaceutical companies are valued based on their model capabilities, computational efficiency, and data barriers, differing from traditional pharmaceutical valuation methods [5] Regulatory Environment - The FDA's recent initiatives, including the introduction of generative AI tools and the appointment of a Chief AI Officer, aim to modernize regulatory processes and enhance the integration of AI in drug approval [6][7] - Chinese pharmaceutical companies looking to enter international markets must adapt to regulatory requirements and ensure compliance with FDA standards [7] Data Utilization Strategies - AI-driven synthetic control arms and real-world data simulations are being recognized by the FDA as valid methods for accelerating international multi-center trial designs [8] - To address data standardization issues in emerging markets, companies should adopt international data models and utilize federated learning techniques to ensure data quality while maintaining patient privacy [8]

为持续向投资者普及ETF基础知识，招商证券携手十大基金公司，联合全景网共同举办2025年招商证 券"招财杯"ETF实盘大赛系列直播，旨在帮助投资者提升资产配置与风险管理能力，促进ETF市场的健 康发展。 2025年7月24日，"招财杯"ETF实盘大赛系列直播邀请到了银华基金指数投资分析师辛迪，一起探讨 《创新药板块崛起，后市还有哪些机会？》。 辛迪表示，经过近几年的快速发展，我国已成为全球创新药领域的重要力量，尤其在研发管线规模、靶 点覆盖及国际化合作方面表现突出，而众多创新药企也将开始进入成果兑现阶段，中国创新药行业或正 在进入厚积薄发的"收获期"。 "总体而言，政策、资本、产业因素共振，中国创新药行业长期成长逻辑坚实。"辛迪进一步表示，"我 认为创新药估值仍有非常充足的上扬空间。" 部分企业业绩超预期，创新药或步入"收获期" 辛迪：从基本面来看，我们认为创新药仍是当前医药板块中产业趋势最为明确且具备未来成长空间的子 行业，全年维度创新药作为医药板块的投资主线不会变化，创新药大时代已然到来。此外，7月中报业 绩预告/快报陆续披露，GLP-1景气赛道、困境反转的原料药等表现亮眼，从半年报情况看，部分企业 H1 ...

Core Viewpoint - The article highlights the strong performance of several funds focusing on innovative pharmaceuticals in Hong Kong, indicating the beginning of a golden era for Chinese pharmaceuticals, with a focus on high-barrier, high-certainty market opportunities in innovative drug companies [2][11]. Fund Performance - The Huatai-PineBridge Hong Kong Advantage Select Fund, managed by Zhang Wei, reported a year-to-date net value growth rate of 133.73%, leading the public fund performance rankings [4]. - The fund's top holdings include Innovent Biologics -B, with a stock price increase of over 250%, and other significant gains from companies like 3SBio and CSPC Pharmaceutical Group, which saw increases of 390% and 90%, respectively [4][11]. - Another fund, the Bank of China Hong Kong Stock Connect Pharmaceutical Fund, managed by Zheng Ning, achieved a year-to-date net value growth rate of 105.43%, ranking among the top three in equity fund performance [4]. Investment Strategies - Fund managers are focusing on core single-product tracks, technology breakthrough segments, and AI-enabled drug development as key investment areas [10][12]. - The article notes a shift in the Chinese innovative drug sector from narrative-driven growth to industry logic-driven growth, with expectations for accelerated globalization and innovation in the next 3 to 5 years [11][12]. Market Outlook - The pharmaceutical industry is expected to see a recovery in domestic medical demand and behavior, with significant policy support for innovative drugs anticipated to improve the payment, access, and investment landscape [11]. - The article emphasizes the importance of cash flow generation from leading innovative drug companies as a key factor for long-term growth [12].

Core Insights - The article highlights the strategic advancements of Shijiazhuang Pharmaceutical Group, particularly its focus on innovation and international collaboration in drug development [1][4][10] Group 1: Innovation and Research - Shijiazhuang Pharmaceutical has achieved significant milestones in innovation, including 11 licensed-out projects and a strategic partnership with AstraZeneca worth $5.33 billion [3][4] - The company has established eight major research and development platforms, with over 200 innovative drug projects currently in progress [8] - The R&D investment is projected to reach 5.7 billion yuan in 2024, maintaining a high growth rate over the past decade [8] Group 2: Globalization and Collaboration - The company emphasizes the importance of international collaboration, viewing licensing as a means to leverage mature markets and advanced research systems [4][10] - Shijiazhuang Pharmaceutical has set up five global R&D centers and has received over 30 overseas clinical approvals, including 16 FDA fast-track or orphan drug designations [4][8] Group 3: Local Ecosystem Support - The local government of Shijiazhuang has actively supported the pharmaceutical industry, providing 290 million yuan in rewards since 2021, with 79.25 million yuan allocated to Shijiazhuang Pharmaceutical [9][10] - The city aims to create a conducive environment for the pharmaceutical sector, with plans to double the company's revenue within five years [9][10]

Group 1 - The core viewpoint of the article highlights the performance and investment strategy of the AI Fund Dongcai Vision Growth Mixed Initiation A (018088), which reported a profit of 652,900 yuan in Q2 2025, with a net value growth rate of 7.02% [2][3] - The fund focuses on long-term investments in pharmaceutical and medical stocks, with a unit net value of 0.866 yuan as of July 18 [2][3] - The fund manager, Sun Chenyang, oversees two funds that have both achieved positive returns over the past year, with the Dongcai Excellence Growth Mixed Initiation A showing the highest growth rate of 51.42% [2][3] Group 2 - The fund's management indicated a strategic shift towards the innovative drug industry chain, emphasizing the potential of AI in drug development, disease diagnosis, and surgical treatment [3] - AI's role in enhancing the accuracy and efficiency of medical diagnoses and treatments is noted, with expectations for increased investment in AI pharmaceuticals and medical applications [3] - The fund's recent performance metrics show a three-month net value growth rate of 23.86%, a six-month growth rate of 36.14%, and a one-year growth rate of 50.53%, positioning it favorably among comparable funds [3] Group 3 - As of June 27, the fund's Sharpe ratio since inception is 0.0874, indicating its risk-adjusted return [7] - The maximum drawdown since inception is reported at 48.55%, with the largest quarterly drawdown occurring in Q1 2024 at 30.58% [11] - The fund has maintained an average stock position of 92.39% since inception, with a peak of 94.38% in H1 2024 [14] Group 4 - As of Q2 2025, the fund's total assets amount to 9.6956 million yuan [16] - The top ten holdings of the fund include companies such as MicroPort Medical, Hongbo Pharmaceutical, and Tigermed, reflecting its focus on the healthcare sector [19]